Viatris, Inc. (VTRS)
NASDAQ:VTRS
Want to see VTRS full AI Analyst Report?
Top Page
Viatris
(NASDAQ:VTRS)
Select Model
Select Model
Rating:61Neutral
Price Target:
$18.00
▲(22.62% Upside)
Action:Reiterated
Date:05/16/26
The score is driven by solid cash generation and a constructive, guidance-reaffirming earnings update with improving China momentum, supported by strong technical uptrends. Offsetting these positives are weak/negative TTM profitability and extended momentum signals (overbought conditions), with valuation only moderately supportive given earnings volatility.
Positive Factors
Strong cash generation & capital flexibility
Sustained positive operating and free cash flow provides durable financial flexibility to fund launches, pay dividends, pursue M&A, and service debt without relying on new capital. This strengthens resilience through industry cycles and supports strategic reinvestment over the next 2–6 months and beyond.
Negative Factors
Negative and volatile reported profitability
Persistent negative trailing‑twelve‑month net income and volatile margins indicate earnings quality issues. Even with strong cash flow, sustained reported losses limit retained earnings and ROE, constraining capital allocation choices and raising execution pressure to convert operational gains into consistent GAAP profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation & capital flexibility
Sustained positive operating and free cash flow provides durable financial flexibility to fund launches, pay dividends, pursue M&A, and service debt without relying on new capital. This strengthens resilience through industry cycles and supports strategic reinvestment over the next 2–6 months and beyond.
Read all positive factors
Viatris Key Performance Indicators (KPIs)
Any
Revenue by Segment
Breaks down revenue across different business segments, highlighting which areas are driving growth and which may need strategic adjustments.
Breaks down revenue across different business segments, highlighting which areas are driving growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyViatris (VTRS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$19.39B
Dividend Yield3.99%
Average Volume (3M)12.25M
Price to Earnings (P/E)22.1
Beta (1Y)1.03
Revenue Growth2.14%
EPS Growth91.93%
CountryUS
Employees32,000
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.26
Shares Outstanding1,164,552,600
10 Day Avg. Volume11,035,954
30 Day Avg. Volume12,246,794
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.99
Price to Sales (P/S)1.02
P/FCF Ratio7.52
Enterprise Value/Market Cap1.65
Enterprise Value/Revenue2.19
Enterprise Value/Gross Profit6.37
Enterprise Value/Ebitda16.90
Forecast
1Y Price Target
$17.86Price Target Upside21.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)2.46
Revenue Forecast (FY)$14.75B
Viatris Business Overview & Revenue Model
Company Description
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, an...
How the Company Makes Money
Viatris makes money primarily by selling prescription and non-prescription medicines globally. Its revenue model is based on (1) high-volume sales of off-patent generic medicines and branded generics, where pricing and market share depend on compe...
Viatris Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 10, 2026
Earnings Call Sentiment Positive
The call portrayed solid operational performance and momentum: top-line revenue growth (3%), strong adjusted EBITDA expansion (10%), sizable China acceleration (+18%), meaningful pipeline progress with multiple upcoming regulatory catalysts, and robust cash flexibility (> $2.5B). These positives were tempered by regional softness (Europe, JANZ), supply constraints in lower-margin generics/ARV, ongoing regulatory timing uncertainty, and policy risk in China. On balance, the positives (broad-based execution, margin control, late-stage pipeline momentum and financial flexibility) outweigh the lowlights.Positive Updates
Revenue Growth and Profitability
Total revenues of $3.5 billion, up 3% year-over-year (operational basis); adjusted EBITDA of $1.0 billion (10% growth year-over-year) and adjusted EPS of $0.59, demonstrating improved earnings leverage versus revenue growth.
Negative Updates
Emerging Markets and Regional Softness
Emerging markets net sales were flat year-over-year, below company expectations; JANZ region net sales decreased ~2% (but came in above expectations) due to increased competition in Australia and government price regulation impact in Japan; Europe net sales declined approximately 1% driven by softer market conditions in select countries and competitive pressure on Dymista.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth and Profitability
Total revenues of $3.5 billion, up 3% year-over-year (operational basis); adjusted EBITDA of $1.0 billion (10% growth year-over-year) and adjusted EPS of $0.59, demonstrating improved earnings leverage versus revenue growth.
Read all positive updates
Company Guidance
Viatris reaffirmed its 2026 guidance after a strong Q1 (total revenues $3.5B, +3% operational; adjusted EBITDA $1.0B; adjusted EPS $0.59; adjusted gross margin 56%; new product revenue $71M; cash generated $348M in Q1, or ~$459M excluding transaction/restructuring/taxes), and said full‑year revenue, adjusted EBITDA and adjusted EPS remain weighted about 52% to the second half with free cash flow also expected to be higher in H2; management now models stronger Greater China growth (mid‑ to high‑single digits, up from prior low‑single digits and +18% in Q1), more than $2.5B of cash available for deployment in 2026, a $140M dividend returned in Q1, an expected ~1% FX tailwind if current rates hold, and on‑track delivery of roughly $120M of cost savings this year while noting some temporary supply and generic competitive headwinds that may partially offset these tailwinds.Viatris Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
52
Neutral
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.56B | 14.30B | 14.74B | 15.43B | 16.26B | 17.89B |
| Gross Profit | 5.01B | 5.01B | 5.62B | 6.44B | 6.50B | 5.58B |
| EBITDA | 1.89B | -395.40M | 2.82B | 3.52B | 6.43B | 4.48B |
| Net Income | -296.50M | -3.51B | -634.20M | 54.70M | 2.08B | -1.27B |
Balance Sheet | ||||||
| Total Assets | 36.83B | 37.19B | 41.50B | 47.69B | 50.02B | 54.84B |
| Cash, Cash Equivalents and Short-Term Investments | 1.80B | 1.45B | 1.09B | 1.18B | 1.47B | 935.00M |
| Total Debt | 14.34B | 14.70B | 14.31B | 18.37B | 19.53B | 23.36B |
| Total Liabilities | 22.18B | 22.48B | 22.87B | 27.22B | 28.95B | 34.35B |
| Stockholders Equity | 14.66B | 14.71B | 18.64B | 20.47B | 21.07B | 20.49B |
Cash Flow | ||||||
| Free Cash Flow | 1.71B | 1.94B | 1.98B | 2.33B | 2.51B | 2.51B |
| Operating Cash Flow | 2.17B | 2.32B | 2.30B | 2.80B | 3.00B | 3.02B |
| Investing Cash Flow | -85.20M | -427.70M | 1.80B | -764.10M | 1.47B | -117.80M |
| Financing Cash Flow | -1.03B | -1.29B | -4.33B | -2.30B | -3.88B | -3.01B |
Viatris Technical Analysis
Positive
14.68
Price Trends
14.61
Positive
14.24
Positive
12.24
Positive
Market Momentum
0.56
Positive
62.08
Neutral
30.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTRS, the sentiment is Positive. The current price of 14.68 is below the 20-day moving average (MA) of 16.06, above the 50-day MA of 14.61, and above the 200-day MA of 12.24, indicating a bullish trend. The MACD of 0.56 indicates Positive momentum. The RSI at 62.08 is Neutral, neither overbought nor oversold. The STOCH value of 30.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VTRS.
Viatris Risk Analysis
Viatris disclosed 17 risk factors in its most recent earnings report. Viatris reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Viatris Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $1.88B | 13.63 | 17.32% | ― | 37.03% | ― | |
67 Neutral | $11.44B | 23.89 | 11.76% | 0.64% | -1.06% | -26.67% | |
61 Neutral | $19.39B | 22.12 | -1.97% | 3.99% | 2.14% | 91.93% | |
61 Neutral | $40.59B | 23.59 | 20.79% | ― | 5.76% | ― | |
60 Neutral | $3.96B | 16.36 | -144.72% | ― | 7.62% | ― | |
52 Neutral | $1.55B | -0.83 | -50.65% | 8.48% | -3.62% | -932.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
VTRS
Viatris
16.65
8.38
101.26%
RDY
Dr Reddy's Laboratories
13.60
-1.08
-7.33%
PRGO
Perrigo Company
11.22
-14.34
-56.10%
TEVA
Teva Pharmaceutical
34.07
16.36
92.38%
ANIP
ANI Pharmaceuticals
82.72
24.40
41.84%
AMRX
Amneal Pharmaceuticals
12.42
5.13
70.37%
Viatris Corporate Events
Executive/Board ChangesShareholder Meetings
Viatris Shareholders Approve Directors, Pay and Auditor
Positive
May 15, 2026
On May 15, 2026, Viatris Inc. held its 2026 annual meeting of shareholders, where investors voted on board membership, executive compensation and the company’s external auditor. Shareholders elected thirteen director nominees to serve until ...
Business Operations and StrategyFinancial Disclosures
Viatris Delivers Strong Q1 2026 Results, Reaffirms Guidance
Positive
May 7, 2026
On May 7, 2026, Viatris reported first-quarter 2026 results showing total revenues of $3.52 billion, up 8% year-on-year on a reported basis and 3% operationally, with U.S. GAAP net earnings of $176 million and adjusted EBITDA of $1.0 billion, up 1...
Executive/Board Changes
Viatris Names Paul Campbell Interim Chief Financial Officer
Neutral
May 4, 2026
On May 1, 2026, Viatris said Chief Financial Officer Theodora “Doretta” Mistras had voluntarily resigned to pursue another opportunity, with her CFO role ending May 8 and her employment concluding May 22, after a transition period. The...
Business Operations and StrategyFinancial Disclosures
Viatris Launches Major Restructuring After Strong 2025 Results
Positive
Feb 26, 2026
On February 26, 2026, Viatris reported robust fourth-quarter 2025 revenues of $3.7 billion and full-year revenues of $14.3 billion, meeting or exceeding its 2025 financial guidance and returning more than $1 billion to shareholders, supported by s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.